Current Medical Research and Opinion
ISSN: 0300-7995 (Print) 1473-4877 (Online) Journal homepage: http://www.tandfonline.com/loi/icmo20
Cephradine in the treatment of chronic recurrent infections of the urinary tract G. H. Brillenburg Wurth & T. K. Clarke To cite this article: G. H. Brillenburg Wurth & T. K. Clarke (1976) Cephradine in the treatment of chronic recurrent infections of the urinary tract, Current Medical Research and Opinion, 4:2, 139-143, DOI: 10.1185/03007997609109294 To link to this article: http://dx.doi.org/10.1185/03007997609109294
Published online: 07 Aug 2008.
Submit your article to this journal
Article views: 3
View related articles
Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=icmo20 Download by: [Deakin University Library]
Date: 07 November 2015, At: 18:30
Current Medical Research and Opinion
Vol. 4, No. 2, 1976
Cephradine in the treatment of cbronic recurrent infections of the urinary tract
G. H. Brillenburg Worth, M.D., and
T. I lo5 organisms per ml) of the same bacteria in pure growth. The organism should also be shown to be sensitive to cephradine using the disc sensitivity test. Once admitted to the trial, patients were treated with 500 mg cephradinet q.i.d. for a period varying from 10 to 15 days. The first follow-up was at 14 days when a second specimen of urine was collected. Final follow-up was after 2 to 3 months when a further specimen of urine was collected. If the second follow-up specimen yielded significant numbers of the original organisms the treatment was considered to have been a failure. If, however, after 2 to 3 months the infection was found to be due to a different organism or the specimen was clear, the treatment was deemed successful. Repeat biochemistry investigations were also made to see if there had been any deterioration in hepatic or renal function. Side-effects due to the therapy, if any, were recorded.
Results Twenty-two patients (17 female and 5 male) were entered in the trial and the age range was 8 to 63 years with a mean of 39.5 (& 16.25) years. The diagnosis and length of time the patients had been attending the hospital are shown in Table I. All patients received 500 mg cephradine 4-times daily except I child, aged 8, who received 250 mg 4-times daily. The bacteriological results are shown in Tables I1 and 111. The results showed that while most of the infections recurred, 8 patients remained clear of infection on their final follow-up; I other patient (No. 21) stopped taking the capsules early in treatment, but on completing a second course remained clear on final follow-up. The mean duration of treatment was 13.5 (f2) days. One patient (No. 17) developed a hypersensitivity rash. There were no significant changes in the biochemical investigations carried out. _____
~~
~
YVelosef‘, trade mark Squibb
140
G. H. Brillenburg Wurth and T. K. Clarke
Table I. Patients included in the study
Downloaded by [Deakin University Library] at 18:30 07 November 2015
Patient No.
Sex
(yrs.)
No. yrs. Diagnosis/Operation attending hospital
Age
1 2
Female Female
41 22
2 5
3 4
Male Female Female
47 8 50
1 2
Female Female
48 39
4 5
Female Female Male Female Female Female Female Male Female Female Male Female Female Female Male
18 44 41 59 41 47 42 52 30 63 40 10 12 57 58
5
6 7 8 9 10 11 12 13 14 15 16 17
18 19 20 21 22
2
5
2 7 2 2 2 2 1
5 1 i l 7
ISSN: 0300-7995 (Print) 1473-4877 (Online) Journal homepage: http://www.tandfonline.com/loi/icmo20
Cephradine in the treatment of chronic recurrent infections of the urinary tract G. H. Brillenburg Wurth & T. K. Clarke To cite this article: G. H. Brillenburg Wurth & T. K. Clarke (1976) Cephradine in the treatment of chronic recurrent infections of the urinary tract, Current Medical Research and Opinion, 4:2, 139-143, DOI: 10.1185/03007997609109294 To link to this article: http://dx.doi.org/10.1185/03007997609109294
Published online: 07 Aug 2008.
Submit your article to this journal
Article views: 3
View related articles
Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=icmo20 Download by: [Deakin University Library]
Date: 07 November 2015, At: 18:30
Current Medical Research and Opinion
Vol. 4, No. 2, 1976
Cephradine in the treatment of cbronic recurrent infections of the urinary tract
G. H. Brillenburg Worth, M.D., and
T. I lo5 organisms per ml) of the same bacteria in pure growth. The organism should also be shown to be sensitive to cephradine using the disc sensitivity test. Once admitted to the trial, patients were treated with 500 mg cephradinet q.i.d. for a period varying from 10 to 15 days. The first follow-up was at 14 days when a second specimen of urine was collected. Final follow-up was after 2 to 3 months when a further specimen of urine was collected. If the second follow-up specimen yielded significant numbers of the original organisms the treatment was considered to have been a failure. If, however, after 2 to 3 months the infection was found to be due to a different organism or the specimen was clear, the treatment was deemed successful. Repeat biochemistry investigations were also made to see if there had been any deterioration in hepatic or renal function. Side-effects due to the therapy, if any, were recorded.
Results Twenty-two patients (17 female and 5 male) were entered in the trial and the age range was 8 to 63 years with a mean of 39.5 (& 16.25) years. The diagnosis and length of time the patients had been attending the hospital are shown in Table I. All patients received 500 mg cephradine 4-times daily except I child, aged 8, who received 250 mg 4-times daily. The bacteriological results are shown in Tables I1 and 111. The results showed that while most of the infections recurred, 8 patients remained clear of infection on their final follow-up; I other patient (No. 21) stopped taking the capsules early in treatment, but on completing a second course remained clear on final follow-up. The mean duration of treatment was 13.5 (f2) days. One patient (No. 17) developed a hypersensitivity rash. There were no significant changes in the biochemical investigations carried out. _____
~~
~
YVelosef‘, trade mark Squibb
140
G. H. Brillenburg Wurth and T. K. Clarke
Table I. Patients included in the study
Downloaded by [Deakin University Library] at 18:30 07 November 2015
Patient No.
Sex
(yrs.)
No. yrs. Diagnosis/Operation attending hospital
Age
1 2
Female Female
41 22
2 5
3 4
Male Female Female
47 8 50
1 2
Female Female
48 39
4 5
Female Female Male Female Female Female Female Male Female Female Male Female Female Female Male
18 44 41 59 41 47 42 52 30 63 40 10 12 57 58
5
6 7 8 9 10 11 12 13 14 15 16 17
18 19 20 21 22
2
5
2 7 2 2 2 2 1
5 1 i l 7
